Chatzikonstantinou Georgios, Zamboglou Nikolaos, Baltas Dimos, Ferentinos Konstantinos, Bon Dimitra, Tselis Nikolaos
Department of Radiotherapy and Oncology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Department of Radiotherapy and Oncology, German Oncology Center, Limassol, Cyprus.
Brachytherapy. 2019 Nov-Dec;18(6):829-834. doi: 10.1016/j.brachy.2019.08.001. Epub 2019 Sep 26.
To evaluate the clinical outcome after CT-guided interstitial high-dose-rate (HDR) brachytherapy for dose escalation in the radiotherapy treatment of inoperable locally advanced non-small-cell lung cancer (NSCLC).
From 2005 to 2015, 16 patients with unresectable NSCLC were treated. Median age was 65.7 years (range, 52-86). The median tumor volume was 95.3 cm (range, 20.0-2000.0). The median prescribed HDR was 15.0 Gy (range, 7.0-32.0) delivered in twice-daily fractions of 6.0-8.0 Gy in 4 patients and in once-daily fractions of 7.0-15.0 Gy in 12 patients, respectively.
After a median followup of 12.5 months, median overall survival and local control was 12.9 and 24.9 months, respectively. The corresponding median overall survival and local control rates at 1, 2, and 3 years were 56.2%, 37.5%, and 12.5% as well as 68.9%, 57.4%, and 43%, respectively. Apart from one Grade 1 cough episode persisting for 1 week and one patient developing a minor hemopneumothorax requiring no postprocedural drainage, no other adverse events were recorded.
CT-guided interstitial HDR brachytherapy is a safe modality for radiation dose escalation which may play a role in the definitive radiotherapy treatment of locally advanced NSCLC.
评估CT引导下高剂量率（HDR）组织间近距离放射治疗用于不可手术切除的局部晚期非小细胞肺癌（NSCLC）放射治疗中剂量递增的临床疗效。
2005年至2015年，对16例不可切除的NSCLC患者进行了治疗。中位年龄为65.7岁（范围52 - 86岁）。中位肿瘤体积为95.3 cm³（范围20.0 - 2000.0 cm³）。中位规定的HDR剂量为15.0 Gy（范围7.0 - 32.0 Gy），4例患者采用每日两次、每次6.0 - 8.0 Gy的分割方式，12例患者采用每日一次、每次7.0 - 15.0 Gy的分割方式。
中位随访12.5个月后，中位总生存期和局部控制期分别为12.9个月和24.9个月。1年、2年和3年相应的中位总生存率和局部控制率分别为56.2%、37.5%、12.5%以及68.9%、57.4%、43%。除1例持续1周的1级咳嗽发作和1例发生少量血气胸但无需术后引流的患者外，未记录到其他不良事件。
CT引导下组织间HDR近距离放射治疗是一种安全的剂量递增方式，可能在局部晚期NSCLC的根治性放射治疗中发挥作用。
